Trasplantes de células madre dopaminérgicas para el Parkinson entran en ensayos clínicos en todo el mundo

Parkinson's disease affects millions worldwide, with motor symptoms arising primarily from the progressive loss of dopaminergic neurons in the substantia nigra. While levodopa and dopamine agonists remain the standard of care, they produce diminishing returns and significant complications over time, including dyskinesias and neuropsychiatric side effects. Cell replacement therapy — directly transplanting dopamine neurons into the striatum — offers a fundamentally different approach aimed at restoring lost circuitry rather than pharmacologically compensating for it.

The concept was pioneered in the 1980s using human fetal ventral mesencephalon (hfVM) tissue. Early case series were promising, with some patients achieving dramatic improvement and even discontinuing medication. However, two NIH-funded double-blind placebo-controlled trials in the 1990s failed their primary endpoints and reported graft-induced dyskinesias (GIDs) in a significant subset of patients. A subsequent EU-funded trial, TransEuro, was severely hampered by fetal tissue supply shortages, underscoring the urgent need for a scalable, reproducible cell source.

The breakthrough came in 2011–2012 when protocols were established for differentiating authentic midbrain dopamine cells from human pluripotent stem cells. This enabled an 'off-the-shelf' manufacturing model with rigorous quality control. Since 2015, 15 clinical trials have been registered globally. Five use human embryonic stem cell (hESC)-derived dopaminergic progenitors, while ten use induced pluripotent stem cell (iPSC)-derived products — some autologous (patient's own cells), others allogeneic (banked donor lines).

The most clinically advanced data comes from BlueRock Therapeutics' Phase I trial (NCT04802733) of Bemdaneprocel in 12 patients with advanced Parkinson's. The high-dose cohort (5.4 million cells) showed a mean 23-point reduction in UPDRS Part III OFF-state motor scores at 24 months versus 8.6 points in the low-dose group, suggesting dose-dependent efficacy. The product was well tolerated with no serious safety concerns reported. BlueRock/Bayer has announced plans for a Phase III placebo-controlled registrational trial. The STEM-PD trial (NCT05635409) in Sweden and the UK completed grafting in 2024 and is collecting follow-up data. S. Biomedics (South Korea) reported a favorable 12-month safety profile for their A9-DPC product. On the iPSC side, Kyoto University completed a 7-patient allogeneic trial, and Aspen Neuroscience has completed recruitment for an autologous iPSC trial in 9 patients.

While the trajectory is encouraging, important questions remain. Most trials are open-label with small sample sizes and lack placebo controls, making it difficult to distinguish true biological effects from placebo responses. Long-term graft survival, the risk of GIDs seen with fetal tissue, the adequacy of immunosuppression for allogeneic products, and the durability of motor benefits all require rigorous evaluation. The field is also watching whether autologous iPSC approaches — despite high manufacturing costs and logistical complexity — offer immunological advantages over allogeneic options.